NovoCure Limited (NVCR)

Every figure this model derived for NVCR, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 22,619,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 93,701,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 638,521,000 AssetsCurrent 2026-06-30
current liabilities 220,710,000 LiabilitiesCurrent 2026-06-30
equity 338,092,000 StockholdersEquity 2026-06-30
interest expense 18,081,000 InterestPaidNet 2026-06-30
ocf -2,815,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 699,193,000 Revenues 2026-06-30
sbc 129,158,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up NVCR on one particular measure came for.

RatioValue
cash operating margin-1.28
current ratio3.13
current ratio reported2.89
deferred revenue growth9.85
dilution pct3.38
fcf margin-3.64
growth cv1.33
interest cover-8.54
operating margin-22.08
owner earnings margin-22.11
revenue growth10.95
revenue growth per share7.33
roic-27.76
rule of 40-11.13
sbc pct revenue18.47

What to be careful about

What this model itself distrusts about NVCR's figures. Written by the derivation as it ran, not added afterwards.